Timothy M. Uyeki

Timothy M. Uyeki

Auto-generated profile, based on publicly available information

Timothy M. Uyeki

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2022 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
ECEric J. Chow
Eric J. Chow
TUTimothy M. Uyeki
Timothy M. Uyeki
HCHelen Y. Chu
Helen Y. Chu

26 August 2022 in The Lancet
Verified
Journal Article
Closed access
TUTimothy M Uyeki
Timothy M Uyeki
DHDavid S Hui
David S Hui
MZMaria Zambon
Maria Zambon
DWDavid E Wentworth
David E Wentworth
AMArnold S Monto
Arnold S Monto

19 December 2018 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
TUTimothy M Uyeki
Timothy M Uyeki
HBHenry H Bernstein
Henry H Bernstein
JBJohn S Bradley
John S Bradley
JEJanet A Englund
Janet A Englund
TFThomas M File
Thomas M File
APAndrew T Pavia
Andrew T Pavia
These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza pandemic. This document addresses new information regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal influenza. It is intended for use by primary care clinicians, obstetricians, emergency medicine providers, hospitalists, laboratorians, and infectious disease specialists, as well as other clinicians managing patients with suspected or laboratory-confirmed influenza. The guidelines consider the care of children and adults, including special populations such as pregnant and postpartum women and immunocompromised patients.

6 June 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
TUTimothy M. Uyeki
Timothy M. Uyeki
SMScott Milton
Scott Milton
CHCherissa Abdul Hamid
Cherissa Abdul Hamid
CWCynthia Reinoso Webb
Cynthia Reinoso Webb
SPSteven M. Presley
Steven M. Presley
CDC. Todd Davis
C. Todd Davis

12 June 2019 in Critical Care
Verified
Journal Article
Open access
PDF file
ECEric J. Chow
Eric J. Chow
JDJoshua D. Doyle
Joshua D. Doyle
TUTimothy M. Uyeki
Timothy M. Uyeki
Annual seasonal influenza epidemics of variable severity result in significant morbidity and mortality in the United States (U.S.) and worldwide. In temperate climate countries, including the U.S., influenza activity peaks during the winter months. Annual influenza vaccination is recommended for all persons in the U.S. aged 6 months and older, and among those at increased risk for influenza-related complications in other parts of the world (e.g. young children, elderly). Observational studies have reported effectiveness of influenza vaccination to reduce the risks of severe disease requiring hospitalization, intensive care unit admission, and death. A diagnosis of influenza should be considered in critically ill patients admitted with complications such as exacerbation of underlying chronic comorbidities, community-acquired pneumonia, and respiratory failure during influenza season. Molecular tests are recommended for influenza testing of respiratory specimens in hospitalized patients. Antigen detection assays are not recommended in critically ill patients because of lower sensitivity; negative results of these tests should not be used to make clinical decisions, and respiratory specimens should be tested for influenza by molecular assays. Because critically ill patients with lower respiratory tract disease may have cleared influenza virus in the upper respiratory tract, but have prolonged influenza viral replication in the lower respiratory tract, an endotracheal aspirate (preferentially) or bronchoalveolar lavage fluid specimen (if collected for other diagnostic purposes) should be tested by molecular assay for detection of influenza viruses. Observational studies have reported that antiviral treatment of critically ill adult influenza patients with a neuraminidase inhibitor is associated with survival benefit. Since earlier initiation of antiviral treatment is associated with the greatest clinical benefit, standard-dose oseltamivir (75 mg twice daily in adults) for enteric administration is recommended as soon as possible as it is well absorbed in critically ill patients. Based upon observational data that suggest harms, adjunctive corticosteroid treatment is currently not recommended for children or adults hospitalized with influenza, including critically ill patients, unless clinically indicated for another reason, such as treatment of asthma or COPD exacerbation, or septic shock. A number of pharmaceutical agents are in development for treatment of severe influenza.

29 March 2019 in Nature Reviews Microbiology
Verified
Journal Article
Open access
PDF file
Jens H. KuhnJens H. Kuhn
Jens H. Kuhn
TATakuya Adachi
Takuya Adachi
NANeill Adhikari
Neill Adhikari
JAJose R. Arribas
Jose R. Arribas
IBIbrahima Elhadj Bah
Ibrahima Elhadj Bah
ZYZabulon Yoti
Zabulon Yoti
The recent large outbreak of Ebola virus disease (EVD) in Western Africa resulted in greatly increased accumulation of human genotypic, phenotypic and clinical data, and improved our understanding of the spectrum of clinical manifestations. As a result, the WHO disease classification of EVD underwent major revision. The recent large outbreak of Ebola virus disease (EVD) in Western Africa resulted in greatly increased accumulation of human genotypic, phenotypic and clinical data, and improved our understanding of the spectrum of clinical manifestations. As a result, the WHO disease classification of EVD underwent major revision.